# Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer

> **NCT02059265** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 35 (actual)

## Conditions studied

- Endometrial Clear Cell Adenocarcinoma
- Ovarian Clear Cell Cystadenocarcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Recurrent Uterine Corpus Cancer

## Interventions

- **DRUG:** Dasatinib
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02059265
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-02-14
- **Primary completion:** 2017-02-06
- **Final completion:** 2023-06-26
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** Interim monitoring
- **Last updated:** 2023-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02059265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02059265, "Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02059265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*